Benzinga · Feb 23, 2026
NASDAQ · BGLC
BioNexus Gene Lab Corp.
Healthcare · Medical - Diagnostics & Research
$1.61
Down-$0.11 (-6.83%)
Updated Sep 14, 2026, 8:38 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 7.51M
- P/E ratio
- -3.27
- Dividend yield
- 0.00%
- 52-week range
- $1.07 – $2.70
- Volume
- 1.83K
- Avg. volume
- 186.93K
Price performance
BGLC price history
1M range · 17 trading sessions · Daily adjusted prices
BGLC closed at $1.61 after 17 trading sessions, up 1.19% for the selected period.
- Last close
- $1.61
- Period change
- +1.19%
- Period low
- $1.40
- Period high
- $1.61
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.5372 | $1.61 | $1.5372 | $1.61 | 1.83K |
| Sep 10, 2026 | $1.48 | $1.48 | $1.48 | $1.48 | 716.01 |
| Sep 9, 2026 | $1.3899 | $1.525 | $1.341 | $1.45 | 18.46K |
| Sep 8, 2026 | $1.35 | $1.43 | $1.35 | $1.40 | 3.07K |
| Sep 4, 2026 | $1.39 | $1.45 | $1.39 | $1.45 | 813 |
| Sep 3, 2026 | $1.44 | $1.49 | $1.44 | $1.47 | 5.92K |
| Sep 1, 2026 | $1.50 | $1.50 | $1.4681 | $1.47 | 1.3K |
| Aug 31, 2026 | $1.48 | $1.49 | $1.48 | $1.49 | 583.1 |
| Aug 28, 2026 | $1.50 | $1.55 | $1.50 | $1.55 | 2.71K |
| Aug 27, 2026 | $1.40 | $1.6094 | $1.40 | $1.50 | 3.68K |
| Aug 26, 2026 | $1.4924 | $1.4924 | $1.24 | $1.43 | 21.85K |
| Aug 24, 2026 | $1.57 | $1.57 | $1.5194 | $1.55 | 810 |
| Aug 21, 2026 | $1.70 | $1.70 | $1.58 | $1.59 | 1.03K |
| Aug 20, 2026 | $1.61 | $1.61 | $1.58 | $1.5865 | 3K |
| Aug 19, 2026 | $1.5734 | $1.655 | $1.57 | $1.57 | 8.71K |
| Aug 18, 2026 | $1.62 | $1.6646 | $1.54 | $1.54 | 6.06K |
| Aug 17, 2026 | $1.63 | $1.88 | $1.55 | $1.5911 | 96.73K |
Latest BGLC news
The latest Smart Investors Daily articles mentioning BGLC.
Stock researchCompany · Overview
BGLC research
Overview
Company profile and research snapshot.
Company profile
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Feb 4, 2026
12 Industrials Stocks Moving In Wednesday's Pre-Market Session
Benzinga · Jan 28, 2026
BioNexus Gene Lab Commences Its 2026 Deployment Phase For VitaGuard Minimal Residual Disease Platform
BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™
globenewswire.com · Dec 3, 2025
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
